Resources Repository
-
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Economics/Finance | North America | Value of Information | State-Transition | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Europe -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Economics/Finance | North America | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine -
Resource PackPublication, Teaching Resource 2022Resource Pack: Decision Analysis & Childhood Obesity
This resource pack on childhood obesity was curated by the Center for Health Decision Science …
This resource pack on childhood obesity was curated by the Center for Health Decision Science to showcase existing cost-effectiveness analyses and motivate students, educators, and others to pursue new applications of decision science methods to the public health challenge of obesity. The resource pack was motivated by the NEJM article entitled Simulation of Growth Trajectories of Childhood Obesity into Adulthood published on November 30, 2017, with CHDS co-authors Zach Ward and Stephen Resch. Citation: Ward Z, Long M,…
Economics/Finance | North America | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Policy/Regulation | Clinical Care | Culture/Society | Food/Agriculture | Health/Medicine -
ArticlePublication 2013Nutritional Policy Changes in SNAP: A Microsimulation and Cost-Effectiveness Analysis
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) …
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) or subsidizing fruits and vegetables purchased with SNAP. The target population was adults in the U.S. and the time horizon was 10 years. Results showed that banning SSB purchases using SNAP benefits would be expected to avert 510,000 diabetes person-years and 52,000 deaths from MIs and strokes over the next decade, with a savings of $2900 per QALY saved. A…
Economics/Finance | North America | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Policy/Regulation | Food/Agriculture | Government/Law | Health/Medicine -
ArticlePublication 2019Health Impact and Cost-Effectiveness of SSB Taxes for Reducing Cancer Burden in the U.S.
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) …
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) tax policy for reducing obesity-related cancer in the U.S. A probabilistic cohort state-transition model, the Diet Cancer Outcome Model (DiCOM), was used to project the effect of a national $0.01 per ounce SSB excise tax on 13 obesity-associated cancers among U.S. adults age 20 and older over their lifetime. Cost-effectiveness was evaluated using both government affordability and societal perspectives. Results showed…
Economics/Finance | North America | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Policy/Regulation | Government/Law | Health/Medicine -
BriefPublication 2019Brief: Safe Routes to School (SRTS) in Houston, Texas
This brief summarizes findings from the CHOICES Learning Collaborative Partnership simulation model of implementing Safe …
This brief summarizes findings from the CHOICES Learning Collaborative Partnership simulation model of implementing Safe Routes to School (SRTS) initiatives in elementary and middle schools in the Houston Independent School District. SRTS aims to help children safely walk and bicycle to school through infrastructure improvements, education, and promotional activities. The analysis compared the costs and outcomes over a 10-year time horizon (2017-2027) of implementing SRTS in Houston with the costs and outcomes associated with not…
Economics/Finance | North America | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Policy/Regulation | Education/Labor | Health/Medicine -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Economics/Finance | North America | Evidence Synthesis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Health Systems | Policy/Regulation | Health/Medicine | Science/Technology -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Economics/Finance | North America | Preferences/Values | Costing Methods | Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Policy/Regulation | Government/Law | Health/Medicine -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Economics/Finance | North America | Test Performance | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Health/Medicine | Global